Clinical Trials Logo

Clinical Trial Summary

This is an open-label, single-arm study to evaluate the safety and efficacy of Ibrutinib in subjects with refractory/relapsed autoimmune hemolytic anemia.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04398459
Study type Interventional
Source Institute of Hematology & Blood Diseases Hospital, China
Contact Jun Shi, PhD
Phone (86)2223900913
Email shijun@ihcams.ac.cn
Status Recruiting
Phase Phase 2
Start date May 1, 2020
Completion date June 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT06021977 - The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia Phase 2